I must say, as a physician-scientist trainee, that this meeting has evolved into THE meeting to attend for relevant advice/mentoring, feedback, and networking opportunities…. We need it now more than ever. Thank you so much for making it possible!

So great to hangout! Let’s do it again next year!

Indeed, poor data abound in this clinical space. These data suggest that half of the HFrecEF who attempt withdrawing GDMT would ultimately benefit from resuming it, but why not try it?

That number is not entirely true for HFrecEF, as reported by Hammer et al. (pubmed.ncbi.nlm.nih.gov/37451602/). Considering HFrEF GDMT costs our patients $100/month on average (after insurance). If a 8 week divergence, why not offer trial-of-withdrawal with a 3-month follow-up?

Sadly, this is a single-center pilot study of 51 patients, so not exactly the evidence I'd need to make conclusions. Even still, (1) less than half of their HFrecEF patients relapsed and (2) no clinical outcomes? Maybe everyone deserves a trial of withdrawal?

Is there any hard evidence for or against GDMT in HFrEF patients with a recovered EF?

"sTAT CoNSuLt cArDioLOgY"

Nice work!

These are remarkable results and while it is early days, this represents new hope for millions of patients worldwide with severe inherited cardiovascular disease. Congrats to the entire team of investigators.

For more on these disorders, see med.stanford.edu/familyheart